AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. (ANTX): 3 pipeline candidates · 1 upcoming catalyst · ~21 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
21.0 months
D/E 0.07 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
1 upcoming, next in ~561d
0 buys · 10 sells (180d)
A transparent, data-derived signal for AN2 Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$178.6M
Cash
$53.5M
Quarterly Burn
$12.1M
Runway
21.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| an2-502998 | Phase 1 |
| AN2-502998 (formerly AN15368) | Phase 1 |
| Epetraborole | Phase 2/Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$48.3M
| Holder | Shares | Value |
|---|---|---|
| commodore capital lp | 2,333,713 | $8.0M |
| millennium management llc | 2,222,502 | $7.6M |
| vanguard capital management llc | 2,022,156 | $6.9M |
| adage capital partners gp, l.l.c. | 1,000,000 | $3.4M |
| ameriprise financial inc | 696,181 | $2.4M |
| sio capital management, llc | 657,200 | $2.2M |
| ally bridge group (ny) llc | 526,315 | $1.8M |
| prosight management, lp | 515,754 | $1.8M |
| bank of nova scotia | 459,194 | $1.6M |
| bank of america corp /de/ | 393,702 | $1.3M |
Showing top 10 of 46 institutional holders of AN2 Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AN2 Therapeutics, Inc.'s pipeline?
AN2 Therapeutics, Inc. (ANTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AN2 Therapeutics, Inc.'s lead drug candidate?
AN2 Therapeutics, Inc.'s most advanced tracked candidate is an2-502998 (Phase 1) for Chagas disease.
What is AN2 Therapeutics, Inc.'s next catalyst?
AN2 Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: leucyl-trna synthetase" — expected December 31, 2027.
What is AN2 Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AN2 Therapeutics, Inc. has approximately 21.0 months of cash runway.
What is AN2 Therapeutics, Inc.'s market capitalization?
AN2 Therapeutics, Inc.'s market capitalization is approximately $178.6M.
Get the full picture on AN2 Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.